Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-5918 in Healthy Volunteers and Patients With Anemia
NCT05773586Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of APG-5918 in anemia (2 arms), sponsored by Ascentage Pharma. Primary endpoint: Treatment-Emergent Adverse Events at 84 days. Started Mar 2023; status: recruiting.
02
Drugs
APG-5918
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05773586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05773586.